FDA Requests More Information From ARCA Biopharma

The Food and Drug Administration requested more information and additional studies from ARCA Biopharma Inc. (Nasdaq: ABIO) for its heart failure medication Gencaro. Shares of the biopharmaceutical plummeted $4.16 to close at $5.13.


About this Entry

This page contains a single entry by published on June 1, 2009 2:45 PM.

Colonial BancGroup CEO To Retire was the previous entry in this blog.

Merge Healthcare To Acquire Etrials is the next entry in this blog.

Find recent content on the main index or look in the archives to find all content.

Powered by Movable Type 5.12